Processa Pharmaceuticals Inc
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline inc… Read more
Processa Pharmaceuticals Inc (PCSA) - Net Assets
Latest net assets as of September 2025: $5.83 Million USD
Based on the latest financial reports, Processa Pharmaceuticals Inc (PCSA) has net assets worth $5.83 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($7.58 Million) and total liabilities ($1.75 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $5.83 Million |
| % of Total Assets | 76.91% |
| Annual Growth Rate | -3.72% |
| 5-Year Change | -92.61% |
| 10-Year Change | N/A |
| Growth Volatility | 734.55 |
Processa Pharmaceuticals Inc - Net Assets Trend (2011–2024)
This chart illustrates how Processa Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Processa Pharmaceuticals Inc (2011–2024)
The table below shows the annual net assets of Processa Pharmaceuticals Inc from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $1.70 Million | -66.00% |
| 2023-12-31 | $4.99 Million | -33.22% |
| 2022-12-31 | $7.47 Million | -70.69% |
| 2021-12-31 | $25.49 Million | +11.10% |
| 2020-12-31 | $22.94 Million | +186.29% |
| 2019-12-31 | $8.01 Million | -17.41% |
| 2018-12-31 | $9.70 Million | +2499.67% |
| 2017-12-31 | $373.16K | +118.86% |
| 2016-12-31 | $-1.98 Million | 0.00% |
| 2015-12-31 | $-1.98 Million | -263.82% |
| 2014-12-31 | $1.21 Million | -27.71% |
| 2013-12-31 | $1.67 Million | -34.79% |
| 2012-12-31 | $2.56 Million | -7.67% |
| 2011-12-31 | $2.78 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Processa Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8721919900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $371.00 | 0.02% |
| Other Components | $88.91 Million | 5242.10% |
| Total Equity | $1.70 Million | 100.00% |
Processa Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Processa Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Concrete Engineering Products
KLSE:8435
|
$6.45 Million |
|
HF Co.
LSE:0EOI
|
$6.45 Million |
|
Pengana Capital Group Ltd
AU:PCG
|
$6.45 Million |
|
Intraco Penta Tbk
JK:INTA
|
$6.45 Million |
|
JKN Global Media Public Company Limited
BK:JKN
|
$6.45 Million |
|
GR.SOU.COP. LS-01
F:E9E
|
$6.45 Million |
|
Millbank Mining Corp.
V:MILL
|
$6.44 Million |
|
PT Sumber Sinergi Makmur Tbk
JK:IOTF
|
$6.44 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Processa Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 4,989,159 to 1,696,171, a change of -3,292,988 (-66.0%).
- Net loss of 11,850,118 reduced equity.
- Share repurchases of 15,902 reduced equity.
- New share issuances of 7,763,079 increased equity.
- Other factors increased equity by 809,953.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-11.85 Million | -698.64% |
| Share Repurchases | $15.90K | -0.94% |
| Share Issuances | $7.76 Million | +457.68% |
| Other Changes | $809.95K | +47.75% |
| Total Change | $- | -66.00% |
Book Value vs Market Value Analysis
This analysis compares Processa Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.23x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.05x to 0.23x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-12-31 | $62.50 | $3.16 | x |
| 2011-12-31 | $24776.94 | $3.16 | x |
| 2012-12-31 | $6373.89 | $3.16 | x |
| 2013-12-31 | $325.07 | $3.16 | x |
| 2014-12-31 | $133.65 | $3.16 | x |
| 2015-12-31 | $-0.38 | $3.16 | x |
| 2016-12-31 | $-176.10 | $3.16 | x |
| 2017-12-31 | $40.07 | $3.16 | x |
| 2018-12-31 | $909.70 | $3.16 | x |
| 2019-12-31 | $725.05 | $3.16 | x |
| 2020-12-31 | $1529.40 | $3.16 | x |
| 2021-12-31 | $831.79 | $3.16 | x |
| 2022-12-31 | $231.87 | $3.16 | x |
| 2023-12-31 | $95.10 | $3.16 | x |
| 2024-12-31 | $13.86 | $3.16 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Processa Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -698.64%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.90x
- Recent ROE (-698.64%) is below the historical average (-232.14%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | -800.00% | -114.29% | 7.00x | 1.00x | $-162.00K |
| 2011 | -33.87% | -4700.00% | 0.00x | 1.91x | $-1.22 Million |
| 2012 | -95.25% | -1270.15% | 0.05x | 1.52x | $-2.70 Million |
| 2013 | -183.66% | -982.05% | 0.11x | 1.76x | $-3.24 Million |
| 2014 | -374.71% | -2260.85% | 0.08x | 2.10x | $-4.65 Million |
| 2015 | 0.00% | -2957.22% | 1.09x | 0.00x | $-3.35 Million |
| 2016 | 0.00% | -2957.22% | 1.09x | 0.00x | $-3.16 Million |
| 2017 | -497.45% | -37126.30% | 0.00x | 7.99x | $-1.89 Million |
| 2018 | -38.81% | 0.00% | 0.00x | 1.36x | $-4.74 Million |
| 2019 | -41.91% | 0.00% | 0.00x | 1.36x | $-4.16 Million |
| 2020 | -83.00% | 0.00% | 0.00x | 1.10x | $-21.33 Million |
| 2021 | -44.84% | 0.00% | 0.00x | 1.04x | $-13.98 Million |
| 2022 | -367.09% | 0.00% | 0.00x | 1.15x | $-28.17 Million |
| 2023 | -222.91% | 0.00% | 0.00x | 1.16x | $-11.62 Million |
| 2024 | -698.64% | 0.00% | 0.00x | 1.90x | $-12.02 Million |
Industry Comparison
This section compares Processa Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Processa Pharmaceuticals Inc (PCSA) | $5.83 Million | -800.00% | 0.30x | $6.45 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |